Clinical trials

INFO & CONTACTS: +39 02 2390 1

Search

Search

Venetoclax and delayed rituximab with ibrutinib consolidation aiming at undetectable minimal residual disease (uMRD) in treatment-naïve patients with chronic lymphocytic leukemia (CLL)

Phase: Phase II-III clinical trials

Principal Investigator: Dott.ssa Farina Lucia

Main Facility: Haematology

Drug: Venetoclax
Targeting triple negative BREAst cancer metabolism with a combination of chemoimmunotherapy and a FASTing-like approach in the preoperative setting: the BREAKFAST 2 trial.

Phase: Phase II-III clinical trials

Principal Investigator: Prof. De Braud Filippo

Main Facility: Medical Oncology 1

Drug: Paclitaxel + Carboplatino + Pembrolizumab
Doxorubicina o Epirubicina + Ciclofosfamide + Pembrolizumab
SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First- Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizum

Phase: Phase II-III clinical trials

Main Facility: Thoracic Oncology Unit

Drug: Pembrolizumab, Olomorasib, Pemetrexed, Carboplatino, Cispatino
Studio di fase 3, randomizzato, in aperto, che confronta l'efficacia e la sicurezza di OSE2101 rispetto a docetaxel in pazienti HLA-A2 positivi con carcinoma polmonare non a piccole cellule (NSCLC) metastatico con resist

Phase: Phase III clinical trials

Principal Investigator: Dr. Lo Russo Giuseppe

Main Facility: Thoracic Oncology Unit

Drug: OSE2101
Retrospective-Prospective Registry of Immune-Mediated Type 1 Diabetes in Solid Tumor Patients Treated with Immune Checkpoint Inhibitors

Phase: Observational, retrospective-prospective, pharmacological study

Principal Investigator: Dott.ssa Indini Alice

Main Facility: Medical Oncology: Melanomas

Drug: Farmaco ICIs (Immune Checkpoint Inhibitors)
RADIANCE: A Monocentric Prospective Randomized Study of Yttrium-90 Radioembolization With or Without Balloon Microcatheter in Patients With Unresectable Hepatocellular Carcinoma

Phase: Non-pharmacological interventional studies

Main Facility: Diagnostic and Interventional Radiology Unit

Drug: Yttrium-90 (radioactive isotope used in microsphere-based therapy)
Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas.

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Haematology

Drug: Selinexor
Phase II study on trabectedin in adults and young adults HEY1-NOCA2 positive skeletal and extra-skeletal mesenchymal chondrosarcoma (MCS)

Phase: Phase II-III clinical trials

Main Facility: Medical Oncology 2

Drug: Trabectedina
Phase II study of lurbinectedin and irinotecan in adult and young adult patients with advanced desmoplastic small round cell tumor (DSRCT).

Phase: Phase II-III clinical trials

Principal Investigator: Dr. Stacchiotti Silvia

Main Facility: Medical Oncology 2

Drug: Lurbinectedina e Irinotecan
Phase I/II, open-label, multi-center study to evaluate the safety and efficacy of glyco-humanized polyclonal antibody directed against tumoral T cells, in patients with relapsed/refractory peripheral T cells lymphoma (PT

Phase: Phase I-II clinical trials

Principal Investigator: Prof. Corradini Paolo

Main Facility: Haematology

Drug: LIS1
Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma patients

Phase: Phase II-III clinical trials

Principal Investigator: Dr. Gronchi Alessandro

Main Facility: General Surgery 7 – Sarcomas

Drug: Trabectedin combined with radiation therapy.
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breastand colorectal cancers

Phase: Phase I clinical trials

Principal Investigator: Dott. Maccauro Marco

Main Facility: Nuclear Medicine

Drug: [177Lu]Lu-NNS309
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Phase: Phase II-III clinical trials

Main Facility: Medical Oncology 1 – Medical Oncology Unit: Melanoma

Drug: Tebentafusp, Pembrolizumab
Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)

Phase: Phase II-III clinical trials

Principal Investigator: Prof. Mazzaferro Vincenzo

Main Facility: Oncologic Surgery 1 – Hepato-Gastro-Pancreatic and Liver Transplantation

Drug: Durvalumab E Tremelimumab
OncoSil Pancreatic cancer post-marketing clinical REgistrY

Phase: Phase IV clinical trials

Main Facility: Oncologic Surgery 1 – Hepato-Gastro-Pancreatic and Liver Transplantation

Drug: Oncosil
Omission of local therapies in women patients with HER2-positive or triple-negative breast cancer. A two arm, phase 2, non-inferiority trial for surveillance in maximum responders to neoadjuvant systemic therapy.

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Gennaro Massimiliano

Main Facility: Breast Surgery

Drug: Not Applicable
Neoadjuvant pembrolizumab plus chemotherapy in locally advanced sinonasal carcinoma (NeoPeSino)

Phase: Phase II-III clinical trials

Principal Investigator: Dott. Alfieri Salvatore

Main Facility: Medical Oncology 3 – Head and Neck Cancers

Drug: Pembrolizumab
Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE)

Principal Investigator: Dott. Alfieri Salvatore

Main Facility: Medical Oncology 3 – Head and Neck Cancers

Drug: Pembrolizumab
Multidisciplinary care pathway tailored on frailty in cancer patients referred to outpatient palliative care.

Phase: Non-pharmacological interventional studies

Principal Investigator: Dott. Massa Giacomo

Main Facility: Palliative Care, Pain Management and Rehabilitation
Monocentric, open-label, single-arm, phase I/II clinical trial to evaluate the use of the ONCOGREEN galenic formulation consisting of indocyanine green (ICG) with autologous extracellular vesicles (EVs) for in vivo diagn

Phase: Phase I-II clinical trials

Principal Investigator: Prof. Mazzaferro Vincenzo

Main Facility: Oncologic Surgery 1 – Hepato-Gastro-Pancreatic and Liver Transplantation

Drug: ONCOGREEN galenic formulation

Clinical trials

Subscribe to the newsletter